Taken together, these data suggest that AKT inhibitors may have clinical potential in combination with anti-HER2 therapy, and that this combination may overcome the limitations associated with anti-HER2 therapy in patients with HER2+ breast cancer carrying PIK3CA mutations, and a highly-activated PI3K pathway. This evidence concerns the gene ERBB2 and breast carcinoma.